XGN News and Press, Exagen Inc. From 01/07/24

2024-01-07 17:18:52 ET More on Akoya Biosciences, Exact Sciences, etc. Guardant Health: Vast Market Opportunity, Challenging Valuation Illumina: The Divestiture Of Grail Could Unlock Significant Shareholder Value Illumina: Conditions Are Met For A Rebound Nan...

CARLSBAD, Calif., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance. ...

2023-11-20 08:37:05 ET Exagen Inc. (XGN) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Ryan Douglas - IR John Aballi - President and CEO Kamal Adawi - CFO Conference Call Participants Kyle Mikson - Canaccord Genu...

2023-11-17 16:21:55 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen For further details see: Exagen files for a $150M mixed shelf offering

2023-11-13 16:28:54 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen For further details see: Exagen GAAP EPS of -$0.31 beats by $0.15, revenue of $13.4M beats by $3.07M

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. Recognized total revenue of $13.4 million for the third quarter of 2023. ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Exagen Inc. (XGN) is expected to report $-0.5 for Q3 2023

2023-11-09 18:23:40 ET More on Exagen Seeking Alpha’s Quant Rating on Exagen Historical earnings data for Exagen Financial information for Exagen For further details see: Exagen licenses lupus nephritis biomarkers from Johns Hopkins

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Johns Hopkins University jointly announced today the execution of an exclusive license agreement. Exagen will focus on the development of novel pat...